Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis

被引:12
作者
Jakimovski, Dejan [1 ,2 ]
Zivadinov, Robert [1 ,2 ,3 ]
Vaughn, Caila B. [1 ]
Ozel, Osman [1 ]
Weinstock-Guttman, Bianca [1 ]
机构
[1] Univ Buffalo State Univ New York, Jacobs Comprehens MS Treatment & Res Ctr, Dept Neurol, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14203 USA
[2] Univ Buffalo State Univ New York, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Jacobs Sch Med & Biomed Sci, 100 High St, Buffalo, NY 14203 USA
[3] Univ Buffalo State Univ New York, Ctr Biomed Imaging, Clin Translat Sci Inst, Buffalo, NY 14203 USA
关键词
Multiple sclerosis; OCT; RNFL; Disability progression; Optic neuritis; OPTICAL COHERENCE TOMOGRAPHY; BRAIN ATROPHY; THICKNESS; DISABILITY; OCT;
D O I
10.1016/j.jns.2021.117552
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Neurodegenerative changes in multiple sclerosis (MS) are associated with long-term disability progression (DP). Optical coherence tomography (OCT) measures may be used to monitor DP. Objective: To determine significant effects driving the changes in OCT-based peripapillary retinal nerve fiber layer (pRNFL) in heterogeneous group of MS patients. Methods: Total of 144 MS patients (109 relapsing-remitting MS and 35 progressive MS (PMS) with mean age at baseline of 47.6 and 56.5 years old, respectively) underwent clinical and OCT examination over 5-year follow-up. All OCT exams were reviewed using the OSCAR-IB criteria. The 5-year DP was determined based on Expanded Disability Status Scale (EDSS) changes and MS clinical trial criteria. Data regarding previous history of MS optic neuritis (MSON) and use of disease modifying treatment (DMT) was derived by in-person interview and review of electronic medical records. Mixed model-type of repeated measure analysis determined effects driving pRNFL change for analysis which utilized all eyes separately. Results: Over an average of 5.3-years follow-up, the MS population demonstrated significant pRNFL thinning (F = 16.108, p < 0.001). The pRNFL thinning was greater due to progressive MS subtype (F = 5.102, p = 0.025), greater age at baseline (F = 4.554, p = 0.034), occurrence of DP (F = 6.583, p = 0.011), and previous history of MSON (F = 7.053, p = 0.008). Use of any or highly potent DMT (natalizumab versus first-line injectable treatments versus no DMT) significantly reduced the pRNFL thinning (F = 8.367, p = 0.004) over the follow-up. Lastly, occurrence of DP in PMS patients older than 50 years old was associated with greater pRNFL thinning (F = 6.667, p = 0.013). Conclusion: Longitudinal pRNFL changes are modified by age, disease subtype, disabiltiy progression, history of MSON, DMT use and their interactions.
引用
收藏
页数:8
相关论文
共 37 条
[1]   Longitudinal study of retinal nerve fiber layer thickness changes in a multiple sclerosis patients cohort: A long term 5 year follow-up [J].
Abalo-Lojo, J. M. ;
Treus, A. ;
Arias, M. ;
Gomez-Ulla, F. ;
Gonzalez, F. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 19 :124-128
[2]   Optic neuritis [J].
Balcer, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1273-1280
[3]   Disease course heterogeneity and OCT in multiple sclerosis [J].
Balk, L. J. ;
Tewarie, P. ;
Killestein, J. ;
Polman, C. H. ;
Uitdehaag, B. M. J. ;
Petzold, A. .
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (09) :1198-1206
[4]   Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study [J].
Balk, Lisanne J. ;
Cruz-Herranz, Andres ;
Albrecht, Philipp ;
Arnow, Sam ;
Gelfand, Jeffrey M. ;
Tewarie, Prejaas ;
Killestein, Joep ;
Uitdehaag, Bernard M. J. ;
Petzold, Axel ;
Green, Ari J. .
JOURNAL OF NEUROLOGY, 2016, 263 (07) :1323-1331
[5]   Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis [J].
Bermel, Robert A. ;
Fedler, Janel K. ;
Kaiser, Peter ;
Novalis, Cindy ;
Schneebaum, Jeff ;
Klingner, Elizabeth A. ;
Williams, Dawn ;
Yankey, Jon W. ;
Ecklund, Dixie J. ;
Chase, Marianne ;
Naismith, Robert T. ;
Klawiter, Eric C. ;
Goodman, Andrew D. ;
Coffey, Christopher S. ;
Fox, Robert J. .
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (09) :1384-1390
[6]   Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing-remitting multiple sclerosis [J].
Bsteh, G. ;
Hegen, H. ;
Teuchner, B. ;
Berek, K. ;
Wurth, S. ;
Auer, M. ;
Di Pauli, F. ;
Deisenhammer, F. ;
Berger, T. .
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (06) :865-871
[7]   Initial high-efficacy disease-modifying therapy in multiple sclerosis A nationwide cohort study [J].
Buron, Mathias Due ;
Chalmer, Thor Ameri ;
Sellebjerg, Finn ;
Barzinji, Ismael ;
Christensen, Jeppe Romme ;
Christensen, Mette Kirstine ;
Hansen, Victoria ;
Illes, Zsolt ;
Jensen, Henrik Boye ;
Kant, Matthias ;
Papp, Viktoria ;
Petersen, Thor ;
Rasmussen, Peter Vestergaard ;
Schafer, Jakob ;
Theodorsdottir, Asta ;
Weglewski, Arkadiusz ;
Sorensen, Per Soelberg ;
Magyari, Melinda .
NEUROLOGY, 2020, 95 (08) :E1041-E1051
[8]   Disease-modifying therapies modulate retinal atrophy in multiple sclerosis A retrospective study [J].
Button, Julia ;
Al-Louzi, Omar ;
Lang, Andrew ;
Bhargava, Pavan ;
Newsome, Scott D. ;
Frohman, Teresa ;
Balcer, Laura J. ;
Frohman, Elliot M. ;
Prince, Jerry ;
Calabresi, Peter A. ;
Saidha, Shiv .
NEUROLOGY, 2017, 88 (06) :525-532
[9]   Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].
Cohen, Jeffrey A. ;
Coles, Alasdair J. ;
Arnold, Douglas L. ;
Confavreux, Christian ;
Fox, Edward J. ;
Hartung, Hans-Peter ;
Havrdova, Eva ;
Selmaj, Krzysztof W. ;
Weiner, Howard L. ;
Fisher, Elizabeth ;
Brinar, Vesna V. ;
Giovannoni, Gavin ;
Stojanovic, Miroslav ;
Ertik, Bella I. ;
Lake, Stephen L. ;
Margolin, David H. ;
Panzara, Michael A. ;
Compston, D. Alastair S. .
LANCET, 2012, 380 (9856) :1819-1828
[10]   pRNFL as a marker of disability worsening in the medium/long term in patients with MS [J].
Cordano, Christian ;
Nourbakhsh, Bardia ;
Devereux, Michael ;
Damotte, Vincent ;
Bennett, Daniel ;
Hauser, Stephen L. ;
Cree, Bruce A. C. ;
Gelfand, Jeffrey M. ;
Green, Ari J. .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (02)